WallStSmart

Airsculpt Technologies Inc (AIRS)vsDaVita HealthCare Partners Inc (DVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 9012% more annual revenue ($13.84B vs $151.84M). DVA leads profitability with a 5.7% profit margin vs -7.4%. DVA earns a higher WallStSmart Score of 70/100 (B-).

AIRS

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.3Quality: 3.5
Piotroski: 2/9Altman Z: 0.75

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AIRSUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$2.40

Current Price

$5.11

$2.71 discount

UndervaluedFair: $2.40Overvalued
DVASignificantly Overvalued (-17.0%)

Margin of Safety

-17.0%

Fair Value

$123.34

Current Price

$192.16

$68.82 premium

UndervaluedFair: $123.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIRS1 strengths · Avg: 10.0/10
EPS GrowthGrowth
200.0%10/10

Earnings expanding 200.0% YoY

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.658/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

Areas to Watch

AIRS4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$382.36M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-11.2%2/10

ROE of -11.2% — below average capital efficiency

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AIRS

The strongest argument for AIRS centers on EPS Growth.

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bear Case : AIRS

The primary concerns for AIRS are Revenue Growth, Market Cap, Piotroski F-Score.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

AIRS profiles as a turnaround stock while DVA is a value play — different risk/reward profiles.

AIRS carries more volatility with a beta of 2.02 — expect wider price swings.

DVA is growing revenue faster at 6.0% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (70/100 vs 34/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Airsculpt Technologies Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Airsculpt Technologies Inc (AIRS) is a pioneering company in the aesthetic medical technology sector, renowned for its innovative AirSculpt® procedure that delivers minimally invasive body contouring with a strong commitment to patient safety and comfort. The company is strategically expanding its network of licensed practitioners, supported by a robust focus on technological advancements, which positions Airsculpt favorably within the rapidly growing non-invasive cosmetic treatment market. As consumer demand for aesthetic solutions continues to rise globally, Airsculpt is well-positioned to enhance its market share and diversify its service offerings, aiming to achieve substantial growth and sustainable value for its investors.

Visit Website →

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Want to dig deeper into these stocks?